Literature DB >> 21777338

Handling botulinum toxins: an updated literature review.

Ada R Trindade De Almeida1, Leticia Cardoso Secco, Alastair Carruthers.   

Abstract

BACKGROUND: Botulinum toxin (BoNT) has been in use since the late 1970s, and over the last 20 years, its use has been extended to new indications in various areas of medicine. During these years of clinical use, some of the initial ideas have changed, and others have remained stable along with increasing experience with and knowledge about BoNTs.
OBJECTIVE: To review the literature and prescribing information on all of the available products and to update the concept of handling toxins (preparations, reconstitution, storage, sterility, and dilution).
METHODS: A review (not Cochrane type analysis) of the medical literature based on relevant databases (MEDLINE, PubMed, Cochrane Library, specialist textbooks, and manufacturer information) was performed.
CONCLUSIONS: Many of the precautions around BoNT use, often recommended by the manufacturers, are described in the clinical literature as too restrictive. The literature suggests that toxins may be sturdier and more-resistant to degradation than previously understood.
© 2011 by the American Society for Dermatologic Surgery, Inc.

Mesh:

Substances:

Year:  2011        PMID: 21777338     DOI: 10.1111/j.1524-4725.2011.02087.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  16 in total

Review 1.  Comparison and overview of currently available neurotoxins.

Authors:  Thomas J Walker; Steven H Dayan
Journal:  J Clin Aesthet Dermatol       Date:  2014-02

2.  Adverse Events Associated With Botox as Reported in a Food and Drug Administration Database.

Authors:  Salma Ahsanuddin; Savannah Roy; Wissam Nasser; Roman Povolotskiy; Boris Paskhover
Journal:  Aesthetic Plast Surg       Date:  2020-10-30       Impact factor: 2.326

Review 3.  A Review of Complications Due to the Use of Botulinum Toxin A for Cosmetic Indications.

Authors:  Nitin Sethi; Sukhbir Singh; Koenraad DeBoulle; Eqram Rahman
Journal:  Aesthetic Plast Surg       Date:  2020-10-13       Impact factor: 2.326

4.  Botulinum toxin type A suppresses arterial vasoconstriction by regulating calcium sensitization and the endothelium-dependent endothelial nitric oxide synthase/soluble guanylyl cyclase/cyclic guanosine monophosphate pathway: An in vitro study.

Authors:  Liang Hu; Ya Feng; Wuchao Liu; Lingjing Jin; Zhiyu Nie
Journal:  Exp Biol Med (Maywood)       Date:  2019-09-23

5.  Treatment of Raynaud's phenomenon with botulinum toxin type A.

Authors:  Xiaolong Zhang; Yong Hu; Zhiyu Nie; Ye Song; Yougui Pan; Ying Liu; Lingjing Jin
Journal:  Neurol Sci       Date:  2015-01-24       Impact factor: 3.307

6.  Evaluating the Effect of Incobotulinumtoxin A for Glabellar, Forehead, and Crow's Feet Lines Using A High Dilution.

Authors:  Sheila C Barbarino; Jani A J van Loghem; Cheryl M Burgess; Niamh Corduff
Journal:  J Clin Aesthet Dermatol       Date:  2021-08-01

7.  Efficacy of Onabotulinum Toxin A (Botox) versus Abobotulinum Toxin A (Dysport) Using a Conversion Factor (1 : 2.5) in Treatment of Primary Palmar Hyperhidrosis.

Authors:  Hanan Mohamed El Kahky; Heba Mahmoud Diab; Dalia Gamal Aly; Nehal Magdi Farag
Journal:  Dermatol Res Pract       Date:  2013-10-22

Review 8.  Use of Botulinum Neurotoxin in Ophthalmology.

Authors:  Emel Başar; Ceyhun Arıcı
Journal:  Turk J Ophthalmol       Date:  2016-12-01

9.  Differential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown lines.

Authors:  Welf Prager
Journal:  Clin Pharmacol       Date:  2013-03-12

Review 10.  Therapeutic efficacy and safety of botulinum toxin type A in trigeminal neuralgia: a systematic review.

Authors:  Yong Hu; Xiaofei Guan; Lin Fan; Mu Li; Yiteng Liao; Zhiyu Nie; Lingjing Jin
Journal:  J Headache Pain       Date:  2013-08-21       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.